Anzeige
Mehr »
Login
Sonntag, 19.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
GOLD-MINEN vor Jahrhundert-Hausse?! Diese Aktie sofort kaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0B7EK | ISIN: JP3431300007 | Ticker-Symbol: JSS
Frankfurt
17.05.24
08:38 Uhr
8,500 Euro
-0,350
-3,95 %
Branche
Pharma
Aktienmarkt
JAPAN
1-Jahres-Chart
NXERA PHARMA CO LTD Chart 1 Jahr
5-Tage-Chart
NXERA PHARMA CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
8,5008,90018.05.

Aktuelle News zur NXERA PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.05.Sosei Group reports Q1 results1
09.05.Nxera Pharma's partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults106Tokyo, Japan and Cambridge, UK, 9 May 2024 - Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) notes that its partner Neurocrine Biosciences Inc. ("Neurocrine"; Nasdaq: NBIX), a leading neuroscience-focused...
► Artikel lesen
09.05.Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 202482Tokyo, Japan and Cambridge, UK, 9 May 2024 - Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter...
► Artikel lesen
17.04.Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years' RSU Plan1
16.04.Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568122NBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing through Phase 2 clinical development under a multi-program collaboration with Neurocrine BiosciencesSuccessful completion...
► Artikel lesen
15.04.Nxera and Handok partner for PIVLAZ supply in South Korea1
15.04.Nxera Pharma Announces Supply And Distribution Deal With Handok For PIVLAZ In South Korea1
15.04.Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for PIVLAZ in South Korea182PIVLAZ is the first drug approved in South Korea for the prevention of Cerebral Vasospasm in patients with Aneurysmal Subarachnoid Hemorrhage (aSAH)PIVLAZ will become commercially available in South...
► Artikel lesen
08.04.Nxera Pharma joins the World Orphan Drug Alliance119Nxera Pharma to represent WODA in Japan and South Korea WODA offers a 'one-stop' solution for biopharma companies seeking to commercialize rare or orphan medicines across global markets Tokyo...
► Artikel lesen
03.04.Nxera Pharma Appoints Experienced Senior Strategy Consultant Patrick Branch as Head of Business Development for Japan and APAC1
01.04.Nxera Pharma is the New Name for Sosei Group134New name expresses the Company's vision to lead the next era of medicine - from Japan, for Japan, and by extension, to the world - and its mission to accelerate the development of life-changing medicines...
► Artikel lesen
27.03.Sosei Group Corporation: Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma97Tokyo, Japan and Cambridge, UK, 27 March 2024 - Sosei Group Corporation ("the Company"; TSE: 4565) announces that the re-election of its Board of Directors and Executive Officers was approved at the...
► Artikel lesen
21.03.Sosei Group Regains Full Ownership From GSK Of Clinic-Ready GPR35 Agonist For Inflammatory Bowel Disease499LONDON (dpa-AFX) - Sosei Group Corp. said it has regained full ownership from GSK of HTL0027477 (formerly GSK4381406), a clinic-ready, highly selective, first-in-class, oral GPR35 agonist in...
► Artikel lesen
21.03.Sosei Group Corporation: Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease88HTL0033744 has been designed by Sosei Heptares to promote mucosal healing and resolve inflammation in people with IBD Tokyo, Japan and Cambridge, UK, 21 March 2024 - Sosei Group Corporation ("Sosei...
► Artikel lesen
21.03.Sosei Group Corporation: Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease98GPR35 is a novel target with an established genetic association to IBDUK regulatory approval received to commence first-in-human studiesReturn of rights follows change in immunology research strategy...
► Artikel lesen
11.03.Boehringer, Sosei Heptares team up in schizophrenia drug deal9
11.03.Boehringer Ingelheim Places €25M Bet on Sosei's Novel Approach to Schizophrenia10
11.03.Boehringer, Sosei Heptares Partner on Schizophrenia Precision Treatment3
11.03.Boehringer boosts schizophrenia strategy with €25M upfront for option on Sosei's GPR52 agonists3
11.03.Boehringer licenses Sosei schizophrenia drugs in €755m deal2
Seite:  Weiter >>
47 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1